Achieving a better cure for cancer

More info

Introduction

CiMaas develops immunotherapy for cancer by optimally engaging the immune system.

Read more about CiMaas Immunotherapy products,
or watch our video.

News /

CiMaas will resume operations

This week CiMaas reached an agreement with several parties for a restart.

We are happy to announce that we are able to continue activities on our cell products. Further details will be communicated soon.

News /

CiMaas files for bankruptcy, aims for restart

To our greatest regret CiMaas has filed for bankruptcy, which became effective Tuesday June 11, 2024. Although CiMaas has great assets in the field of NK cell immunotherapy for cancer using its proprietary feeder cell technology and expansion methodology, it was unable to raise enough financial resources to perform the required clinical studies.